CGTN
23.2.2021 10:38:10 CET | Business Wire | Press release
A total of 832 counties, 128,000 villages and nearly 100 million people were living in poverty. This was the reality that China had to face. The task of providing support to them all wasn't easy, and making sure that everyone receives the exact help they needed was even harder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005505/en/
"Who were these people and where were they located? If you are intent on leaving no one behind, then you have to locate each and every one of them and tailor relief measures accordingly," said Lin Wanlong, professor of economics and management at China Agriculture University.
In November 2013, during an inspection tour of central China's Hunan, Chinese President Xi Jinping first raised the concept of "targeted poverty alleviation." To crystalize it, he said one should "seek truth from facts, tailor measures to suit local conditions, give targeted guidance, and be meticulous about the work." These points have become the guiding principle in China's fight against poverty.
The first step of the targeted poverty alleviation campaign is to locate poverty through accurate identification, which means specifying survey data by matching it with individuals and households. Are there any better-off families in impoverished counties? Are there any poor households in rich townships? How does one differentiate whether a family really needs help? These were the first challenges that the campaign had to overcome.
"When I was just assigned to the township, I was informed that there were over 2,300 households and about 8,000 people living in poverty. But nobody knew who exactly they were," said Zhu Shengjiang, head of Yeping Town in Jiangxi Province's Ruijin City.
In a township of over 70,000 people, a poor population of over 8,000 was scattered among 399 villager groups. Zhu and his colleagues had to go door-to-door and look meticulously into their respective family conditions. Once poverty is identified, they would set up file for the households and log their information onto system.
The ultimate aim of poverty alleviation is to ensure people don't have to worry about food and clothing and have access to compulsory education, basic medical services and safe housing. Commonly known as the "two assurances and three guarantees," these are the key indicators for poverty relief officials to identify who exactly needs help.
"In each household, we look at things like whether there is sufficient working capacity, whether the child is receiving education and whether all family members are healthy. If the answer is no in all these categories, then we have found a household that really needs help," said Zeng Nenggui, director of poverty relief office in Ruijin City.
The launching of a national digital database has enabled data to cover each and every registered village, household and individual, which not only ensures the accuracy of poverty identification but helps nail down the causes of poverty for those who are in the system.
"These households are like a benchmark. What we do is to analyze their conditions and come up with tailor-made measures to lift them out of poverty," said Lu Chunsheng, director of the Information Center of the National Bureau of Rural Development. "For example, if a family remains poor because they couldn't receive proper education, our relief measures should include granting student loans and subsidies. If poverty is caused by a family member's poor health conditions, we then should provide them with sufficient healthcare."
Prescribing the right remedy is the key. Under President Xi's guidance, the targeted poverty alleviation campaign has five key measures.
Development & Production
All 832 registered counties have formulated industrial plans to fight against poverty, with over 300,000 industrial bases in farming, planting and processing being constructed on site.
Relocation
More than 96 million registered people have moved into over 2.66 million newly constructed houses, all equipped with water, electricity, gas and internet. Transportation is convenient with better roads built.
Ecological compensation
Over 1.1 million registered people have been employed as ecological forest rangers, directly lifting a total of 3 million out of poverty.
Education
About 200,000 students who dropped out of school due to poverty have now returned to school. More than 8 million students from poor families who failed to continue their studies or get employed after finishing high school have received vocational education for free.
Social security
Since 2016, a total of 19.36 million registered people have been included in the subsistence allowance, support and relief system.
To ensure that poverty is truly lifted, the strictest assessment system has been put in place. For each county to declare it has officially left poverty behind, it has to be thoroughly assessed by a third-party inspection team.
"We have never encountered such rigorous measures," said Zhang Shibin, former director of the poverty alleviation office of Yunnan Province's Luquan Yi and Miao Autonomous County. " During the third-party inspection, village officials are not even allowed to follow these teams into the village."
The targeted poverty alleviation campaign has perfectly embodied China's practical and down-to-earth approach in battling poverty, opening up a path that accommodates the country's realities while reflecting unique Chinese characteristics.
Original article: here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
